Glutamine antagonist DRP-104 suppresses tumor growth and enhances response to checkpoint blockade in KEAP1 mutant lung cancer
Keap1 mutant lung tumors were injected into mice and once lung tumors formed the mice were treated with anti-PD1, DRP-104, or the combination of the drugs. Immune cells and tumor cells were isolated from the lungs and ExCITE-seq was performed. Overall design: 2 mice (G1 vs G2) per treatment arm: Isotype + Vehicle (HT4), DRP-104  + Isotype (HT2), anti-PD1 + Vehicle (HT3), and DRP-104 + anti-PD1 (HT1). After 5 days of treatment, immune and tumor cells were analyzed by ExCITE-seq with libraries for gene expression, ADT, and TCR